237 related articles for article (PubMed ID: 28360333)
1. Detailed Characterization of the In Vitro Pharmacological and Pharmacokinetic Properties of
Jensen AA; McCorvy JD; Leth-Petersen S; Bundgaard C; Liebscher G; Kenakin TP; Bräuner-Osborne H; Kehler J; Kristensen JL
J Pharmacol Exp Ther; 2017 Jun; 361(3):441-453. PubMed ID: 28360333
[TBL] [Abstract][Full Text] [Related]
2. The selective 5-HT
Jensen AA; Halberstadt AL; Märcher-Rørsted E; Odland AU; Chatha M; Speth N; Liebscher G; Hansen M; Bräuner-Osborne H; Palner M; Andreasen JT; Kristensen JL
Biochem Pharmacol; 2020 Jul; 177():113979. PubMed ID: 32298690
[TBL] [Abstract][Full Text] [Related]
3. Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.
Halberstadt AL; van der Zee JVF; Chatha M; Geyer MA; Powell SB
Psychopharmacology (Berl); 2019 Feb; 236(2):821-830. PubMed ID: 30448990
[TBL] [Abstract][Full Text] [Related]
4. 25CN-NBOH: A Selective Agonist for in vitro and in vivo Investigations of the Serotonin 2A Receptor.
Märcher Rørsted E; Jensen AA; Kristensen JL
ChemMedChem; 2021 Nov; 16(21):3263-3270. PubMed ID: 34288515
[TBL] [Abstract][Full Text] [Related]
5. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice.
Fantegrossi WE; Gray BW; Bailey JM; Smith DA; Hansen M; Kristensen JL
Psychopharmacology (Berl); 2015 Mar; 232(6):1039-47. PubMed ID: 25224567
[TBL] [Abstract][Full Text] [Related]
6. Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice.
Buchborn T; Lyons T; Knöpfel T
Front Pharmacol; 2018; 9():17. PubMed ID: 29467649
[TBL] [Abstract][Full Text] [Related]
7. The serotonin 2A receptor agonist 25CN-NBOH increases murine heart rate and neck-arterial blood flow in a temperature-dependent manner.
Buchborn T; Lyons T; Song C; Feilding A; Knöpfel T
J Psychopharmacol; 2020 Jul; 34(7):786-794. PubMed ID: 32048564
[TBL] [Abstract][Full Text] [Related]
8. Acute serotonin 2A receptor activation impairs behavioral flexibility in mice.
Amodeo DA; Hassan O; Klein L; Halberstadt AL; Powell SB
Behav Brain Res; 2020 Oct; 395():112861. PubMed ID: 32814148
[TBL] [Abstract][Full Text] [Related]
9. Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT
Eshleman AJ; Wolfrum KM; Reed JF; Kim SO; Johnson RA; Janowsky A
Biochem Pharmacol; 2018 Dec; 158():27-34. PubMed ID: 30261175
[TBL] [Abstract][Full Text] [Related]
10. The Chronic Treatment With 5-HT
Tsybko AS; Ilchibaeva TV; Filimonova EA; Eremin DV; Popova NK; Naumenko VS
Neurochem Res; 2020 Dec; 45(12):3059-3075. PubMed ID: 33095437
[TBL] [Abstract][Full Text] [Related]
11. A quantitative method for the selective 5-HT2A agonist 25CN-NBOH in rat plasma and brain.
Breusova K; Ernstsen KG; Palner M; Linnet K; Kristensen JL; Kretschmann AC
J Pharm Biomed Anal; 2021 May; 199():114016. PubMed ID: 33784574
[TBL] [Abstract][Full Text] [Related]
12. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
[TBL] [Abstract][Full Text] [Related]
13. The selective 5-HT2A receptor agonist 25CN-NBOH does not affect reversal learning in mice.
Odland AU; Kristensen JL; Andreasen JT
Behav Pharmacol; 2021 Aug; 32(5):448-452. PubMed ID: 33595957
[TBL] [Abstract][Full Text] [Related]
14. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.
Dunlop J; Watts SW; Barrett JE; Coupet J; Harrison B; Mazandarani H; Nawoschik S; Pangalos MN; Ramamoorthy S; Schechter L; Smith D; Stack G; Zhang J; Zhang G; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2011 Jun; 337(3):673-80. PubMed ID: 21402690
[TBL] [Abstract][Full Text] [Related]
15. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.
Rosenzweig-Lipson S; Zhang J; Mazandarani H; Harrison BL; Sabb A; Sabalski J; Stack G; Welmaker G; Barrett JE; Dunlop J
Brain Res; 2006 Feb; 1073-1074():240-51. PubMed ID: 16430874
[TBL] [Abstract][Full Text] [Related]
16. Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice.
Halberstadt AL; Sindhunata IS; Scheffers K; Flynn AD; Sharp RF; Geyer MA; Young JW
Neuropharmacology; 2016 Aug; 107():364-375. PubMed ID: 27020041
[TBL] [Abstract][Full Text] [Related]
17. Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT
Poulie CBM; Pottie E; Simon IA; Harpsøe K; D'Andrea L; Komarov IV; Gloriam DE; Jensen AA; Stove CP; Kristensen JL
J Med Chem; 2022 Sep; 65(18):12031-12043. PubMed ID: 36099411
[TBL] [Abstract][Full Text] [Related]
18. Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model.
Canal CE; Booth RG; Morgan D
Neuropharmacology; 2013 Jul; 70():112-21. PubMed ID: 23353901
[TBL] [Abstract][Full Text] [Related]
19. Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands.
Canal CE; Cordova-Sintjago T; Liu Y; Kim MS; Morgan D; Booth RG
J Pharmacol Exp Ther; 2013 Dec; 347(3):705-16. PubMed ID: 24080681
[TBL] [Abstract][Full Text] [Related]
20. A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.
Canal CE; Morgan D; Felsing D; Kondabolu K; Rowland NE; Robertson KL; Sakhuja R; Booth RG
J Pharmacol Exp Ther; 2014 May; 349(2):310-8. PubMed ID: 24563531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
